Show Me the Data®: Evidence-Based Strategies to Leverage Immunogenicity in Hepatocellular Carcinoma

Target Audience
This educational program is directed toward medical oncologists, surgical oncologists, and radiation oncologists interested in the treatment of HCC. Hepatologists, gastroenterologists, nurse practitioners, physician assistants, nurses, and other health care professionals involved in the treatment and management of patients with HCC will also be invited to participate.

Activity Overview
This online, on-demand virtual symposium brings together renowned experts in hepatocellular carcinoma (HCC) to discuss challenging clinical cases. In this educational program, these experts substantiate their treatment choices with the appropriate supporting evidence at each decision point. Participants will gain insights on how experts in the field of HCC leverage key data sets to support decision-making regarding when to initiate systemic therapy, how to appropriately sequence or combine therapies, how to monitor the patient, and best practices for adverse event management.

This educational activity is an archive of the live virtual symposium held on June 9, 2021.

Learning Objectives
Upon completion of this activity, participants should be better able to:

Identify clinically relevant aspects of HCC biology and biomarkers in the context of treatment planning and therapeutic development
Evaluate safety and efficacy data from recent clinical trials that inform treatment decision-making across lines of care in HCC
Assess available data that inform treatment decision-making across multiple lines of care with consideration for prior therapies and toxicities
Apply relevant data and patient/disease factors to develop personalized therapeutic sequencing strategies for HCC